Related Experiment Videos
Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism
Abstract:
In 15 patients (8 men, 7 women), aged 44-81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.
Insights
Mesulergine effectively treated Parkinsonism symptoms in patients, though efficacy declined after 18 months. Adjusting levodopa dosage helped manage worsening symptoms over three years.
Area of Science:
- Neurology
- Pharmacology
Background:
- Idiopathic parkinsonism is a progressive neurodegenerative disorder.
- Current treatments like levodopa have limitations and side effects.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of mesulergine in treating idiopathic parkinsonism.
- To assess mesulergine's effectiveness across different patient groups based on prior treatment.
Main Methods:
- A 3-year observational study involving 15 patients with idiopathic parkinsonism.
- Patients were categorized into three groups based on prior treatment: no levodopa, levodopa/decarboxylase inhibitor, or levodopa/decarboxylase inhibitor and bromocriptine.
- Efficacy was assessed using rating scales, and side effects were monitored.
Main Results:
- Mesulergine demonstrated efficacy in improving rigidity, tremor, and akinesia across all patient groups.
- A decline in mesulergine's efficacy was noted after 18 months, necessitating levodopa dosage adjustments.
- Fine motor skills improved more than walking, which was impacted by freezing; levodopa-sparing effects were temporary.
- Hallucinations and dyskinesias were the most common side effects; orthostatic hypotension was not an issue.
Conclusions:
- Mesulergine is effective for idiopathic parkinsonism symptoms but not sufficient as monotherapy.
- Long-term use requires careful management, including levodopa dosage adjustments, to sustain therapeutic benefits.
- Mesulergine shows a promising but temporary levodopa-sparing effect, with side effects primarily being hallucinations and dyskinesias.